PR-104

PR-104

Chemical structure of PR-104

PR-104 is a hypoxia-activated prodrug that is being investigated for its potential use in cancer therapy. It is designed to target hypoxic regions within tumors, which are areas with low oxygen levels that are often resistant to conventional therapies.

Mechanism of Action

PR-104 is a prodrug, meaning it is inactive until it is metabolized into its active form. Under hypoxic conditions, PR-104 is converted into PR-104H, a cytotoxic agent that can damage DNA and kill cancer cells. This conversion is facilitated by reductase enzymes that are more active in low-oxygen environments.

Clinical Development

PR-104 has been evaluated in several clinical trials to assess its safety and efficacy in treating various types of cancer, including leukemia and solid tumors. The drug is often studied in combination with other chemotherapeutic agents to enhance its therapeutic effects.

Hypoxia in Tumors

Hypoxia is a common feature of solid tumors due to their rapid growth and inadequate blood supply. Hypoxic tumor cells are often more aggressive and resistant to treatment, making them a significant target for novel therapies like PR-104.

Related pages

• Cancer therapy
• Prodrug
• Hypoxia
• Chemotherapy